Alfacell, Phoqus Pharmaceuticals, Watson Pharmaceuticals, Stem Cell Sciences, Kythera Biopharmaceuticals and ISPE have all had people on the move in the world of pharmaceutical manufacturing.
US biopharma Alfacell has appointed Lawrence Kenyon to the newly created position of chief operating officer.
Kenyon also joins the company's board of directors, whilst retaining his previous responsibilities as executive vice president, CFO and corporate secretary. His new COO role will involve Kenyon taking over management of all aspects of the firm's day-to-day operations.
Phoqus Pharmaceuticals also recently announced the appointment of a new COO, naming Michel Grandjean as the new post holder.
Grandjean will take on his new role at the UK firm as of 1 January 2008, taking responsibility for leading the manufacturing and supply chain operations at Phoqus, including commercial manufacture of the firm's lead product, Chronocort.
Grandjean will be leaving contract manufacturer Patheon to take up his new position.
Specialty pharma Watson Pharmaceuticals recently announced the appointment of its new CFO, Mark Durand.
Durand joins the company from his former position as CFO and senior VP of finance and business development at generics firm Teva, where he was responsible for all financial and business development activities related to the firm's North American operations.
Stem Cell Sciences also announced a change in management this week, with the appointment of Alastair Riddell as the firm's new CEO.
Riddell replaces the company's founder, Peter Mountford, who has moved to the position of Chief Technology Officer.
Riddell has held positions in a number of firms, including Surface Therapeutics, paradigm Therapeutics, Pharmagene, Centocor and Xoma Europe.
Kythera Biopharmaceuticals has landed itself a new VP of regulatory affairs, naming Deepak Chadha as the new incumbent.
Chadha joins the firm from his most recent role as VP of global regulatory affairs at Allergan Medical, and previously held positions at Biomeasure and Stryker Biotech.
The International Society for Pharmaceutical Engineering (ISPE) also recently announced its newly elected international board of directors for 2007-2008.
Revealing the new board at its annual meeting in Las Vegas, ISPE named its new leaders including new Chair Bruce Davis (AstraZeneca global capital director) and Vice Chair Charles Hoiberg (Pfizer executive director, regulatory CMC).